© 2022 MJH Life Sciences and Drug Topics. All rights reserved.
© 2022 MJH Life Sciences™ and Drug Topics. All rights reserved.
October 17, 2022
US Preventive Services Task Force hasn't endorsed screening for atrial fibrillation. Findings from these two studies might factor into a reconsideration.
September 15, 2022
The review focused on Remicade (infliximab) and Enbrel (etanercept). The annualized discontinuation rate was 21% among patients who had undergone nonmedical switching to biosimilars. However, the rates were similar to those found in some separate analyses of patients on reference biologics.
September 13, 2022
Several provisions in the law are designed to protect and foster the biosimilar market. But some representatives of the sector see CMS drug price negotiation as a threat to profit margins.
September 12, 2022
Some companies are using the interchangeability designation as a marketing ploy.
August 18, 2022
The Inflation Reduction Act puts a $35 cap on monthly out-of-pocket expenses for insulin. The catch: It applies only to people covered by Medicare. The competition gearing up could drive down costs for others.
August 16, 2022
New research should give expectant mothers some peace of mind.